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Mother’s own milk is the first choice for the feeding and nutrition of preterm and term
newborns. When mother’s own milk is unavailable or in short supply donor human
milk (DM) could represent a solution. Heat treatment and cold storage are common
practices in Human Milk Banks (HMBs). Currently, Holder pasteurization process is the
recommended heat treatment in all international guidelines. This method is thought to
lead to a good compromise between the microbiological safety and nutritional/biological
quality of DM.Moreover, storage of refrigeratedmilk is a common practice in HMBs and in
NICUs. Depending on the length and on the type of storage, human milk may lose some
important nutritional and functional properties. The available data on oxidative stress
markers confirm that pasteurization and refrigeration affected this important elements
to variable degrees, even though it is rather difficult to quantify the level of deterioration.
Nonetheless, clinical practice demonstrates that many beneficial properties of human
milk are preserved, even after cold storage and heat treatment. Future studies should be
focused on the evaluation of new pasteurization techniques, in order to achieve a better
compromise between biological quality and safety of DM.
Keywords: donor human milk, human milk, human milk bank, oxidative stress, heat treatment, refrigeration,
pasteurization
INTRODUCTION
Human milk (HM) is the gold standard for feeding and nutrition for preterm and term newborns.
Mother’s own milk is the first choice for improving short and long-term outcomes for all
neonates (1–3). HM benefits are mediated by different components, including specific and
immunomodulatory molecules and species-specific factors. Breastmilk could be considered as a
dynamic system and species-specific nourishment for newborns (4). Human Donor Milk (DM)
can replace breastmilk when unavailable or lacking, although safe procedures for milk storage and
conservation are required (5, 6). Currently, several reviews that show the advantages of donor milk,
the World Health Organization and the American Academy of Pediatrics suggest the use of DM as
a substitute of mother milk (1, 3).
Heat treatment on milk delivered to Human Milk Banks (HMBs) is critical for milk safety:
pasteurization, indeed, inactivates bacterial and viral agents (5). Pasteurization is a process
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consisting of three main phases: rapid heating, stationary
temperature phase and rapid cooling. Currently, the Holder
Pasteurization (HoP) method, providing a temperature of
62,5◦C for 30min, is fundamental for HMBs constitution
and its use is suggested by international guidelines (5, 6) as
HoP represents the best compromise between nutritional and
biological characteristics and microbiological safety (7–11).
Cold storage of HM is a routine not only in HMB but also
at home and in the hospitals, especially in Neonatal Intensive
Care Units. According to the length and on the typology of
storage, HMmay lose some significant nutritional and functional
characteristics. The maximum refrigeration time for human
milk ranges between 24 h and 8 days, according to the current
advices on safe HM storage (12–14). Such variability replicates
the heterogeneity of the scientific sources, which is ascribable
to differences in the study design and in methodological
approach (5, 14, 15). Recently, Slutzah et al. concluded that
HM may be stored for 96 h at 4◦C without affecting the
overall milk integrity, as determined by bacterial growth,
white cell count, pH, osmolality, and concentration of selected
biological factors (sIgA, lactoferrin, total fat, and total proteins)
(16, 17).
On the other hand, detailed data on the effects of storage,
in terms of oxidative stress markers, on mother’s milk are still
lacking. Thus, the present paper is aimed at reviewing published
evidences, and at comparing results on the effects of HoP and
the refrigerated storage on the oxidative stress markers of human
milk.
SEARCH METHODOLOGY
The literature review was performed by electronic searches of
MEDLINE, EMBASE, CINHAL, and the Cochrane Library. The
electronic search used the following keywords and MeSH terms:
donor milk, banked milk, milk bank, milk banking, (human
milk OR donormilk) ANDHolder pasteurization AND oxidative
stress, (human milk OR donor milk) AND pasteurization AND
oxidative stress, (human milk OR donor milk) AND storage
AND oxidative stress, (human milk OR donor milk) AND heat
treatment AND oxidative stress, (human milk OR donor milk)
AND cold treatment AND oxidative stress, (human milk OR
donor milk) AND refrigeration AND oxidative stress(donor milk
OR Holder pasteurization) AND oxidative stress, (donor milk
OR cold storage) AND oxidative stress, (donor milk OR cold
storage) AND oxidative stress.
The research was performed in December 2017 and no limits
concerning publication date were set.
Considering differences between the research protocols
published to date, we focused our review on studies with an
experimental design that:
- define exactly the pasteurization method (62.5–63◦C for
30min)
- define exactly the refrigeration method (4◦C for maximum
96 h)
- compare the same samples of HM before and after the heat or
the cold treatments.
HEAT TREATMENT
The effects of HoP on oxidative stress markers are evaluated only
in three studies.
Oxidative status was assessed, on raw and pasteurized
breastmilk, by the evaluation of oxidants molecules and the
activity of oxidants scavengers. Silvestre et al. showed that HoP
does not significantly influence the levels of malondialdehyde
while glutathione peroxidase activity, glutathione concentrations
and total antioxidant capacity result seriously compromised.
This result shows a reduction on oxidative scavenging systems
of HM (18). Other authors (19) did not find changes in
hexanal and malondialdehyde concentration and in the total
antioxidant capacity (measured by means of oxygen radical
absorbance capacity essay) thus meaning no lipid oxidation
neither contraction of antioxidant systems.
Moreover, Peila et al. analyzed the effects of HoP on an
emergent oxidative stress marker of the HM: the hemeoxygenase-
1 (HO-1) (20). HO-1 is a stress-inducible rate-limiting enzyme
and it is involved in different cytoprotective effects, due to
its multiple catalytic by-products. HO-1 is active in HM and
shows no significant reduction in its activity after HoP process,
even after being corrected for milk maturation degree and
gestational age (20). The protective effect of HO-1, similarly
to other milk antioxidant scavenger systems, could be found
in its antioxidant activity which induces the conversion of
free heme into three final products: (i) biliverdin, which is
metabolized in bilirubin that shows antioxidant activity), (ii)
carbon monoxide, a neurotransmitter and vasodilator with
antiapoptotic and anti-inflammatory activities, and (iii) iron
(Fe2+) which is bound by specific proteins (20–24). Furthermore,
HO-1 could have an immunoregulatory role in addition to
its enzymatic activity, related to its capacity to bind specific
receptors and to modulate the immune response (20). Indeed,
extracellular stress proteins, including Heat Shock Proteins
(HSP), rise as fundamental mediators of signaling and transport
(25, 26). Behavioral stress influences the release of this proteins
by the cell as well as the exposition to immunological
“danger signals” (24). HSP released into extracellular fluid
can bind receptors exposed by adjacent cells and begin
the signal transduction cascades, likewise, the transport of
molecules like antigenic peptides and chaperokines with
immunomodulatory effect (20, 27). In particular, Li Volti et al.
through a molecular modeling approach, found an important
immunoregulatory receptor that could be the natural ligands of
HO-1(20, 28). Nevertheless, the integration of experimental data
with informatics data shows HO-1 role in the modulation of
immune system (28).
Considering the various functions of HO-1 in the body,
data reported in literature showing underlying a reduction in
NEC incidence in preterm fed with DM compared to those fed
with formula (7–11) and, the unclear pathophysiology of NEC
(immature gastrointestinal epithelium, impaired immunological
defenses, enteral feeding, and bacterial colonization), it is possible
to argue that human milk HO-1 may play a role in the
development and regulation of the immune system of the
gastrointestinal tract (20).
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Over the past decades the food industry and, in particular,
the dairy industry tested innovative alternatives to standard
pasteurization in an effort to maximize the preservation of food
taste and nutritional features. Alternative processing techniques
that are currently being tested to investigate their effect on HM
include high-temperature–short-time pasteurization (HTST),
high pressure processing (HPP), ultraviolet (UV) irradiation and
(thermo-) ultrasonic processing (29).
HTST is a thermal pasteurization method that is well
established in the dairy industry (“fresh” bovine milk is usually
pasteurized by means of HTST). The method involves a thin
layered milk flow being heated rapidly to 72◦C and being kept
at this temperature for a few seconds (usually 15 s), and then
immediately cooled down. This method preserves most of the
sensory features and nutritional values of the milk, and ensures
a lower degradation of proteins and vitamins (29). Silvestre et al.
(18) investigated oxidative stress markers (reduced glutathione,
glutathione peroxidase activity, malondialdehyde, and total
antioxidant capacity), and showed that the pasteurization of
HM implies a decrease in its antioxidant properties, especially
in the glutathione balance, but HTST caused a smaller loss in
antioxidant potential than HoP.
COLD STORAGE
The effects of refrigerated storage at 4◦C on oxidative stress
markers are evaluated only in four studies.
Concerning the insurgence of lipid peroxidation and the
creation of oxidation molecules, contrasting data have been
reported in literature (30–32). Some studies reveal that cold
storage of HM may reduce its antioxidants capacity (32) and
increasemalondialdehyde concentration (30). On the other hand,
the study of Giribaldi et al. showed that the refrigerated storage at
4◦C for 96 h did not affect the oxidative status of HM, evaluating
the total antioxidant capacity, conjugated dienes, thiobarbituric
acid reactive species and malondialdehyde concentration (14,
17). Their results did not indicate any evidence of lipid
peroxidation, same Michalski et al reported (17, 31). The
oxidative status of the HM during cold storage is particularly
relevant for preterm newborns whose disorders are mainly due
to disequilibrium between antioxidant capacity and oxidative
stress, having a reduced antioxidant capacity and being often
exposed to oxidant stress (32, 33). Moreover, the recent study of
Peila et al. evaluated the effects of prolonged refrigerated storage
on an important marker in HM: Adrenomedullin (AM) (34).
AM is a C-amidated peptide, implicated in response to hypoxia
and inflammation, which are linked also with neovascularization.
Recent studies indicate that AM is synthesized also in the
mammary gland and secreted in breast milk (35–37). AM
levels in preterm milk (milk produced to mother who have
delivered preterm, Gestational Age <37 weeks) are significant
higher compared to term milk (milk produced to mother who
have delivered at term, Gestational Age >37 weeks). This
protein is not thermostable at 4◦C: AM is significant reduced
(56%) at 24 h and is nearly undetectable at 96 h (34). AM is
a regulatory peptide and its expression was demonstrated in
several tissues and biologic fluids such as plasma, cerebro-spinal
fluid, sweat, amniotic fluid and urine (38–40). AM has been
involved in the modulation of several physiological functions
including cardiovascular tone, central brain activity (41–44),
bronchodilation, renal function, hormone secretion, cell growth-
differentiation, and immune response(45–52).Moreover, AMhas
been tested for its connection to ischemia-reperfusion injury
whilst in healthy infants has been proved to contribute in
the cascade of events sustaining fetal/neonatal cardiovascular
adaptation (43–47). AM has been also taken into consideration
for the analysis of beneficial/side-effects of in-utero vasodilation
therapeutic strategies in pregnancies complicated by fetal chronic
hypoxia (43–47). Concerning this, relation with AM and the
occurrence of adverse neurological outcome has been reported
in infants with congenital heart disease (47). Considering these
important functions, it is possible to hypothesize that the
existence of the active peptide AM in HM, and its variability
in concentrations throughout different milk maturation degrees,
gestational pathologies and gestational age at delivery, could
have some direct impact in infants development due to the
various physiological activities that have been related to it. In
the gastrointestinal tract, immunoreactive AM has been found
in human stomach, duodenum, jejunum, ileum and colon (47,
53, 54), and specific binding sites have been also found in rat
stomach (54). This arrangement supposes a role for AM in the
regulation of secretory-motor functions in the gastrointestinal
tract, as well as in its development during the embryogenesis
and the period immediately following birth. Since the developing
intestine in the neonate is believed considered to be one of the
main target organs for the growth factors present in human milk,
Pio et al. proved that milk has a growth-promoting function
on human small intestinal epithelial cell line (Int-407) (35,
36). These authors hypothesize that since MoAb-G6 partially
blocks the milk-induced growth, AM may be one of the growth
factors present in milk (35, 36). AM has also been characterized
as an agent with antimicrobial activity against gastrointestinal
microorganisms (36, 51, 52). This activity could be relevant for
the protection of the neonate against gastroenteritis produced
by intestinal pathogens. Eventually, since some peptides are
absorbed from the neonatal gastrointestinal tract and appear
intact in plasma (36, 55), AM could also exercise an activity in
the modulation of tissue growth as well as in the regulation of the
immune system (36, 55).
CONCLUSION
Multiple studies have been conducted to evaluate the effects
of pasteurization and cold storage on breast milk and the
results indicate that these treatments affect the concentration and
activity of the constituents of HM to varying degrees. However,
many studies show the persistence of the benefits of donated milk
compared to artificial milk in the nutrition of preterm infants.
With regard to the effects on oxidative stress markers, the data are
currently lacking and contrasting. Many questions remain to be
answered in particular, future studies will have to be conducted
to clarify the aspects not yet investigated on the markers of
oxidative stress and on biological properties in relation to the
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HoP and cold treatments of breast milk. Future investigations
must be aimed at improving the biological quality and safety of
DM and should be: (i) designed to investigate the pre-analytical
stability of these components according to storage procedures;
(ii) intended to evaluate innovative test technologies, such as
metabolomics; (iii) focused on new pasteurization techniques
(high-temperature short-term pasteurization, thermoultrasonic
treatment, high-pressure processing, and Ohmic heat treatment);
(iv) aimed to evaluate analytical techniques able to assess the
protein changes due to thermic treatments, as well as their
interaction with sugars and lipids; (v) evaluated the effects of
HoP on other biomarkers involved in growth and developing of
newborns.
Moreover further studies will aimed at elucidating the protein
stability during industrial processes for the preparation of
artificial milk such as pasteurization and spray-drying, which
have already been shown to affect milk composition and
properties.
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